AstraZeneca defends patent for Forxiga in Russia

4 July 2024

UK pharma major AstraZeneca (LSE: AZN) is defending a patent for its diabetes drug Forxiga (dapagliflozin) in Russia, as part of the recent decision taken by the Russian Supreme Court, reports The Pharma Letter’s local correspondent.

In accordance with the decision of the Court taken on June 4, 2024, the patent for Forxiga held by AstraZeneca was issued and extended in accordance with the law and remains valid until May 15, 2028.

The original Forxiga drug from AstraZeneca is produced in Russia at a plant in the Kaluga region under a special investment contract that AstraZeneca signed with the Ministry of Industry and Trade of the Russian Federation and the Kaluga region.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK